内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理

2021-03-10 Mayo Clin Proc . 2021 Mar 10

术前管理

2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内

中文标题：

2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理

英文标题：

Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement

发布机构：

发布日期：

2021-03-10

简要介绍：

2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内分泌、激素以及泌尿系统用药的术前管理提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=632b71c0020e673d, title=2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理, enTitle=Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement, guiderFrom=Mayo Clin Proc . 2021 Mar 10, authorId=0, author=, summary=2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内, cover=https://img.medsci.cn/2021330/1617116171763_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Mar 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内分泌、激素以及泌尿系统用药的术前管理提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=111064, tagName=术前管理)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=943, guiderKeyword=内分泌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=21110, appHits=125, showAppHits=0, pcHits=546, showPcHits=20985, likes=1, shares=18, comments=16, approvalStatus=1, publishedTime=Tue Mar 30 23:50:47 CST 2021, publishedTimeString=2021-03-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 30 22:57:13 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 09:10:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理.pdf)])
2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理.pdf
下载请点击：
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-11-06 ms9000000892709945

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-08-17 ms1000001256854968

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-06-23 ms2000000895029841

    很好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-05-21 ms9000000564533451

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

拓展阅读

2014 美国内分泌学会女性应用雄性激素治疗指南

美国内分泌学会(TES,The Endocrine Society) · 2014-10-03

2015 ESPE共识指南：先天性甲状腺功能减退症筛查、诊断和管理

欧洲儿科内分泌学会(ESPE,European Society for Paediatric Endocrinology) · 2015-03-16

2016 AACE/ACE/AME指南：甲状腺结节的诊断和管理

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2016-05-16

2017 NANETS共识指南：中肠神经内分泌肿瘤的监测和医学管理

北美神经内分泌肿瘤学会(NANETS,North American Neuroendocrine Tumor Society) · 2017-06-10

2017 NANETS共识指南：手术治疗小肠神经内分泌肿瘤

北美神经内分泌肿瘤学会(NANETS,North American Neuroendocrine Tumor Society) · 2017-06-10

2017 TES科学声明：内分泌性高血压的筛查

美国内分泌学会(TES,The Endocrine Society) · 2017-03-22